Encouraging First OS Data from 1L Higher-Risk (HR) MDS Patients in the BEXMAB Ph 1/2 Trial Announced July 28, 2026
Ph 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with indolent NHL in the watch-and-wait setting July 28, 2026
Preliminary data from Ph 2 MRD translational clinical trial of IMNN-001 + SOC N/ACT & bevacizumab in women with 1L advanced ovarian cancer announced July 28, 2026
Positive Data Demonstrating 100% ORR and 18.2-Month Median OS with Alpha DaRT + Pembrolizumab combo in Locally Advanced or Metastatic Head and Neck Cancer Reported July 28, 2026
Durable Clinical Activity of Darlifarnib + Cabozantinib Reported in Cabozantinib-Naïve Clear Cell RCC Patients July 28, 2026
Ivonescimab + Chemo Shows Consistent, Favorable OS Results in Western and Asian Patients in Updated Analysis from Global Ph 3 HARMONi Study July 28, 2026
Supplemental Application accepted for Toripalimab + Chemo as Perioperative Treatment for Resectable Stage II-III NSCLC July 28, 2026
FDA Grants Priority Review for TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer July 28, 2026
Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1L advanced ER-positive breast cancer July 28, 2026
